XOMA Corporation (XOMA)
USD 19.49
(-1.62%)
USD 19.49
(-1.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 145.58 Million USD | 789.42% |
| 2022 | 16.36 Million USD | -33.7% |
| 2021 | 24.68 Million USD | -36.48% |
| 2020 | 38.86 Million USD | -24.89% |
| 2019 | 51.73 Million USD | 14.97% |
| 2018 | 45 Million USD | 14.95% |
| 2017 | 39.14 Million USD | -48.41% |
| 2016 | 75.88 Million USD | -1.69% |
| 2015 | 77.18 Million USD | -10.8% |
| 2014 | 86.53 Million USD | -37.64% |
| 2013 | 138.76 Million USD | 64.79% |
| 2012 | 84.2 Million USD | 33.61% |
| 2011 | 63.02 Million USD | 24.41% |
| 2010 | 50.66 Million USD | 43.52% |
| 2009 | 35.29 Million USD | -64.19% |
| 2008 | 98.57 Million USD | 16.66% |
| 2007 | 84.49 Million USD | -34.83% |
| 2006 | 129.65 Million USD | 39.04% |
| 2005 | 93.24 Million USD | 31.58% |
| 2004 | 70.87 Million USD | 0.33% |
| 2003 | 70.63 Million USD | -15.05% |
| 2002 | 83.14 Million USD | 14.7% |
| 2001 | 72.48 Million USD | 34.73% |
| 2000 | 53.8 Million USD | 19.03% |
| 1999 | 45.2 Million USD | 21.83% |
| 1998 | 37.1 Million USD | 10.42% |
| 1997 | 33.6 Million USD | 46.09% |
| 1996 | 23 Million USD | 63.12% |
| 1995 | 14.1 Million USD | -25.4% |
| 1994 | 18.9 Million USD | 20.38% |
| 1993 | 15.7 Million USD | -24.52% |
| 1992 | 20.8 Million USD | 5.05% |
| 1991 | 19.8 Million USD | -71.95% |
| 1990 | 70.6 Million USD | -15.35% |
| 1989 | 83.4 Million USD | 230.95% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 143.28 Million USD | 4.53% |
| 2024 Q1 | 137.07 Million USD | -5.84% |
| 2023 FY | 145.58 Million USD | 789.42% |
| 2023 Q1 | 19.13 Million USD | 16.92% |
| 2023 Q2 | 15.53 Million USD | -18.82% |
| 2023 Q3 | 18.13 Million USD | 16.69% |
| 2023 Q4 | 145.58 Million USD | 702.98% |
| 2022 Q4 | 16.36 Million USD | 3.56% |
| 2022 Q2 | 19.26 Million USD | 0.16% |
| 2022 Q1 | 19.23 Million USD | -22.08% |
| 2022 FY | 16.36 Million USD | -33.7% |
| 2022 Q3 | 15.8 Million USD | -17.96% |
| 2021 Q3 | 18.91 Million USD | -1.33% |
| 2021 FY | 24.68 Million USD | -36.48% |
| 2021 Q1 | 38.17 Million USD | -1.77% |
| 2021 Q4 | 24.68 Million USD | 30.48% |
| 2021 Q2 | 19.17 Million USD | -49.77% |
| 2020 Q2 | 49.46 Million USD | -2.39% |
| 2020 FY | 38.86 Million USD | -24.89% |
| 2020 Q3 | 47.68 Million USD | -3.59% |
| 2020 Q4 | 38.86 Million USD | -18.51% |
| 2020 Q1 | 50.67 Million USD | -2.06% |
| 2019 FY | 51.73 Million USD | 14.97% |
| 2019 Q3 | 60.3 Million USD | 5.17% |
| 2019 Q2 | 57.34 Million USD | 10.9% |
| 2019 Q4 | 51.73 Million USD | -14.22% |
| 2019 Q1 | 51.7 Million USD | 14.9% |
| 2018 FY | 45 Million USD | 14.95% |
| 2018 Q1 | 37.67 Million USD | -3.77% |
| 2018 Q4 | 45 Million USD | -0.02% |
| 2018 Q3 | 45 Million USD | 23.77% |
| 2018 Q2 | 36.36 Million USD | -3.48% |
| 2017 Q4 | 39.14 Million USD | -14.24% |
| 2017 FY | 39.14 Million USD | -48.41% |
| 2017 Q1 | 53.73 Million USD | -29.19% |
| 2017 Q2 | 53.26 Million USD | -0.89% |
| 2017 Q3 | 45.64 Million USD | -14.29% |
| 2016 Q1 | 60.13 Million USD | -22.09% |
| 2016 Q2 | 59.01 Million USD | -1.87% |
| 2016 Q4 | 75.88 Million USD | 35.81% |
| 2016 Q3 | 55.87 Million USD | -5.31% |
| 2016 FY | 75.88 Million USD | -1.69% |
| 2015 Q4 | 77.18 Million USD | -28.67% |
| 2015 FY | 77.18 Million USD | -10.8% |
| 2015 Q3 | 108.21 Million USD | 17.46% |
| 2015 Q2 | 92.12 Million USD | 0.74% |
| 2015 Q1 | 91.45 Million USD | 5.69% |
| 2014 Q1 | 105.88 Million USD | -23.69% |
| 2014 Q2 | 97.49 Million USD | -7.93% |
| 2014 Q3 | 89.05 Million USD | -8.65% |
| 2014 FY | 86.53 Million USD | -37.64% |
| 2014 Q4 | 86.53 Million USD | -2.84% |
| 2013 Q1 | 89.85 Million USD | 6.7% |
| 2013 Q4 | 138.76 Million USD | 32.73% |
| 2013 Q2 | 93.8 Million USD | 4.4% |
| 2013 Q3 | 104.54 Million USD | 11.45% |
| 2013 FY | 138.76 Million USD | 64.79% |
| 2012 Q2 | 82.05 Million USD | 0.27% |
| 2012 Q4 | 84.2 Million USD | -15.48% |
| 2012 Q3 | 99.63 Million USD | 21.43% |
| 2012 FY | 84.2 Million USD | 33.61% |
| 2012 Q1 | 81.83 Million USD | 29.84% |
| 2011 FY | 63.02 Million USD | 24.41% |
| 2011 Q1 | 58.27 Million USD | 15.03% |
| 2011 Q2 | 55.46 Million USD | -4.83% |
| 2011 Q3 | 55.52 Million USD | 0.12% |
| 2011 Q4 | 63.02 Million USD | 13.51% |
| 2010 Q3 | 33 Million USD | -1.83% |
| 2010 Q4 | 50.66 Million USD | 53.52% |
| 2010 Q1 | 35.36 Million USD | 0.18% |
| 2010 FY | 50.66 Million USD | 43.52% |
| 2010 Q2 | 33.61 Million USD | -4.94% |
| 2009 Q4 | 35.29 Million USD | -19.19% |
| 2009 Q1 | 95.82 Million USD | -2.79% |
| 2009 Q2 | 85.1 Million USD | -11.19% |
| 2009 Q3 | 43.68 Million USD | -48.67% |
| 2009 FY | 35.29 Million USD | -64.19% |
| 2008 Q3 | 114.16 Million USD | 3.66% |
| 2008 Q2 | 110.13 Million USD | 60.65% |
| 2008 Q1 | 68.55 Million USD | -18.87% |
| 2008 Q4 | 98.57 Million USD | -13.65% |
| 2008 FY | 98.57 Million USD | 16.66% |
| 2007 Q2 | 81.31 Million USD | 6.75% |
| 2007 Q4 | 84.49 Million USD | 4.11% |
| 2007 FY | 84.49 Million USD | -34.83% |
| 2007 Q3 | 81.16 Million USD | -0.19% |
| 2007 Q1 | 76.17 Million USD | -41.24% |
| 2006 Q3 | 94.49 Million USD | 0.06% |
| 2006 Q2 | 94.43 Million USD | -1.6% |
| 2006 Q1 | 95.97 Million USD | 2.92% |
| 2006 Q4 | 129.65 Million USD | 37.21% |
| 2006 FY | 129.65 Million USD | 39.04% |
| 2005 FY | 93.24 Million USD | 31.58% |
| 2005 Q1 | 80.57 Million USD | 13.69% |
| 2005 Q2 | 86.45 Million USD | 7.3% |
| 2005 Q3 | 85.01 Million USD | -1.66% |
| 2005 Q4 | 93.24 Million USD | 9.68% |
| 2004 FY | 70.87 Million USD | 0.33% |
| 2004 Q2 | 67.35 Million USD | -6.73% |
| 2004 Q3 | 66.11 Million USD | -1.84% |
| 2004 Q1 | 72.21 Million USD | 2.23% |
| 2004 Q4 | 70.87 Million USD | 7.2% |
| 2003 FY | 70.63 Million USD | -15.05% |
| 2003 Q1 | 85.88 Million USD | 3.29% |
| 2003 Q2 | 91.15 Million USD | 6.13% |
| 2003 Q3 | 93.05 Million USD | 2.09% |
| 2003 Q4 | 70.63 Million USD | -24.09% |
| 2002 Q2 | 80.13 Million USD | 6.18% |
| 2002 Q4 | 83.14 Million USD | 3.01% |
| 2002 FY | 83.14 Million USD | 14.7% |
| 2002 Q1 | 75.47 Million USD | 4.11% |
| 2002 Q3 | 80.71 Million USD | 0.73% |
| 2001 Q3 | 60.19 Million USD | 0.76% |
| 2001 Q4 | 72.48 Million USD | 20.42% |
| 2001 Q2 | 59.74 Million USD | 0.75% |
| 2001 Q1 | 59.29 Million USD | 10.21% |
| 2001 FY | 72.48 Million USD | 34.73% |
| 2000 FY | 53.8 Million USD | 19.03% |
| 2000 Q1 | 51.48 Million USD | 13.91% |
| 2000 Q3 | 50.6 Million USD | 0.51% |
| 2000 Q4 | 53.8 Million USD | 6.32% |
| 2000 Q2 | 50.34 Million USD | -2.22% |
| 1999 Q3 | 39.9 Million USD | -8.28% |
| 1999 Q4 | 45.2 Million USD | 13.28% |
| 1999 Q1 | 38.8 Million USD | 4.58% |
| 1999 FY | 45.2 Million USD | 21.83% |
| 1999 Q2 | 43.5 Million USD | 12.11% |
| 1998 FY | 37.1 Million USD | 10.42% |
| 1998 Q2 | 35.7 Million USD | 10.19% |
| 1998 Q4 | 37.1 Million USD | 3.92% |
| 1998 Q3 | 35.7 Million USD | 0.0% |
| 1998 Q1 | 32.4 Million USD | -3.57% |
| 1997 Q3 | 23.9 Million USD | 1.7% |
| 1997 Q4 | 33.6 Million USD | 40.59% |
| 1997 FY | 33.6 Million USD | 46.09% |
| 1997 Q2 | 23.5 Million USD | 2.17% |
| 1997 Q1 | 23 Million USD | 0.0% |
| 1996 Q1 | 7.2 Million USD | -48.94% |
| 1996 FY | 23 Million USD | 63.12% |
| 1996 Q3 | 12.8 Million USD | 2.4% |
| 1996 Q4 | 23 Million USD | 79.69% |
| 1996 Q2 | 12.5 Million USD | 73.61% |
| 1995 FY | 14.1 Million USD | -25.4% |
| 1995 Q4 | 14.1 Million USD | 90.54% |
| 1995 Q2 | 17.1 Million USD | -1.72% |
| 1995 Q1 | 17.4 Million USD | -7.94% |
| 1995 Q3 | 7.4 Million USD | -56.73% |
| 1994 Q4 | 18.9 Million USD | 17.39% |
| 1994 Q1 | 16 Million USD | 1.91% |
| 1994 Q2 | 15.9 Million USD | -0.63% |
| 1994 Q3 | 16.1 Million USD | 1.26% |
| 1994 FY | 18.9 Million USD | 20.38% |
| 1993 Q3 | 15.6 Million USD | -1.27% |
| 1993 Q2 | 15.8 Million USD | -20.2% |
| 1993 FY | 15.7 Million USD | -24.52% |
| 1993 Q1 | 19.8 Million USD | -4.81% |
| 1993 Q4 | 15.7 Million USD | 0.64% |
| 1992 FY | 20.8 Million USD | 5.05% |
| 1992 Q2 | 19.4 Million USD | 23.57% |
| 1992 Q4 | 20.8 Million USD | -5.02% |
| 1992 Q1 | 15.7 Million USD | -20.71% |
| 1992 Q3 | 21.9 Million USD | 12.89% |
| 1991 FY | 19.8 Million USD | -71.95% |
| 1991 Q3 | 13.4 Million USD | 11.67% |
| 1991 Q4 | 19.8 Million USD | 47.76% |
| 1991 Q1 | 66.1 Million USD | -6.37% |
| 1991 Q2 | 12 Million USD | -81.85% |
| 1990 Q3 | 66.8 Million USD | -16.71% |
| 1990 Q1 | 83.1 Million USD | -0.36% |
| 1990 FY | 70.6 Million USD | -15.35% |
| 1990 Q2 | 80.2 Million USD | -3.49% |
| 1990 Q4 | 70.6 Million USD | 5.69% |
| 1989 Q2 | 82.9 Million USD | 0.0% |
| 1989 Q3 | 84 Million USD | 1.33% |
| 1989 Q4 | 83.4 Million USD | -0.71% |
| 1989 FY | 83.4 Million USD | 230.95% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 56.644% |
| Alkermes plc | 933.53 Million USD | 84.406% |
| Agenus Inc. | 462.29 Million USD | 68.509% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 96.406% |
| Aptorum Group Limited | 5.25 Million USD | -2669.398% |
| Ardelyx, Inc. | 130.76 Million USD | -11.331% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 69.569% |
| Bicycle Therapeutics plc | 224.41 Million USD | 35.128% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -11.804% |
| ChromaDex Corporation | 26.5 Million USD | -449.193% |
| Chimerix, Inc. | 19.74 Million USD | -637.301% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -313.849% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -100.615% |
| CRISPR Therapeutics AG | 346.76 Million USD | 58.018% |
| Precision BioSciences, Inc. | 140.92 Million USD | -3.307% |
| Dyadic International, Inc. | 2.34 Million USD | -6119.637% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -795.161% |
| Fortress Biotech, Inc. | 165.93 Million USD | 12.269% |
| Lantern Pharma Inc. | 2.73 Million USD | -5213.755% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -103.665% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -4025.569% |
| Incyte Corporation | 1.59 Billion USD | 90.857% |
| IO Biotech, Inc. | 17.55 Million USD | -729.232% |
| Jaguar Health, Inc. | 45.86 Million USD | -217.403% |
| Novavax, Inc. | 2.57 Billion USD | 94.34% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -303.738% |
| Opthea Limited | 264.6 Million USD | 44.981% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -11.379% |
| ContextLogic Inc. | 206 Million USD | 29.33% |
| MiMedx Group, Inc. | 96.33 Million USD | -51.126% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -203.153% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -4025.38% |
| NextCure, Inc. | 14.99 Million USD | -870.727% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -3501.682% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -2080.321% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -211.474% |
| Vaxcyte, Inc. | 167.44 Million USD | 13.06% |
| PDS Biotechnology Corporation | 33.25 Million USD | -337.714% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 38.107% |
| Pharming Group N.V. | 244.07 Million USD | 40.354% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1121.104% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -13.92% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2103.328% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -2103.328% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -76.604% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -2091.48% |
| Acelyrin, Inc. | 86.35 Million USD | -68.587% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -11105.004% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -912.449% |
| Summit Therapeutics Inc. | 125.25 Million USD | -16.225% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -1435.816% |
| Senti Biosciences, Inc. | 52.57 Million USD | -176.921% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -111.67% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 3.915% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -7342.74% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -10800.264% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 35.82% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1454.18% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 35.993% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 70.561% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -1233.883% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -429.17% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1102.673% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 70.082% |
| Immix Biopharma, Inc. | 3.72 Million USD | -3811.566% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -285.01% |
| MEI Pharma, Inc. | 8.35 Million USD | -1642.43% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -401.74% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 58.116% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 0.198% |
| Fortress Biotech, Inc. | 165.93 Million USD | 12.269% |
| Precigen, Inc. | 41.64 Million USD | -249.582% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -191.568% |
| AlloVir, Inc. | 45.01 Million USD | -223.403% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -11.695% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -5.646% |
| ImmuCell Corporation | 18.81 Million USD | -673.743% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -415.766% |
| Onconetix, Inc. | 23.18 Million USD | -528.017% |
| PureTech Health plc | 125.58 Million USD | -15.923% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1526.592% |
| Elevation Oncology, Inc. | 34.28 Million USD | -324.654% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -5854.192% |
| Seer, Inc. | 39.36 Million USD | -269.821% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -135.437% |
| Innoviva, Inc. | 568.55 Million USD | 74.395% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -434.67% |
| ESSA Pharma Inc. | 3.49 Million USD | -4065.294% |
| GlycoMimetics, Inc. | 6.9 Million USD | -2009.221% |
| GT Biopharma, Inc. | 6.63 Million USD | -2094.784% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 44.937% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 46.534% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -73.256% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -1389.462% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -435.831% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -4413.027% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -97.351% |
| Aptose Biosciences Inc. | 15.8 Million USD | -820.885% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -1218.697% |
| Soligenix, Inc. | 7.27 Million USD | -1901.126% |
| Century Therapeutics, Inc. | 175.94 Million USD | 17.256% |
| Kura Oncology, Inc. | 51.66 Million USD | -181.793% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -20.034% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -3422.381% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -2101.137% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 42.367% |
| Autolus Therapeutics plc | 263.9 Million USD | 44.837% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -1288.857% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -63.829% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -210.412% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 58.742% |
| GRI Bio, Inc. | 2.69 Million USD | -5297.849% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -17882.053% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -368.238% |
| IGM Biosciences, Inc. | 220.17 Million USD | 33.88% |
| INmune Bio, Inc. | 18.86 Million USD | -671.816% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 43.239% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -446.434% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5255.344% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -4338.055% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -149.046% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -51.395% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 45.009% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 82.312% |
| Verastem, Inc. | 71.18 Million USD | -104.509% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -196.039% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -277.365% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -197.515% |
| Histogen Inc. | 5.69 Million USD | -2455.38% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -3219.496% |
| Surrozen, Inc. | 8.14 Million USD | -1687.354% |
| Organovo Holdings, Inc. | 2.74 Million USD | -5197.671% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46284.034% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -158.901% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -781.662% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -184.876% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -17506.047% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -14.879% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -1246.269% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 3.518% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -5483.458% |
| Apollomics, Inc. | 14.15 Million USD | -928.616% |
| Amarin Corporation plc | 279.58 Million USD | 47.93% |
| Mesoblast Limited | 188.79 Million USD | 22.891% |
| Turnstone Biologics Corp. | 14.14 Million USD | -928.979% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 19.475% |
| Synaptogenix, Inc. | 5.52 Million USD | -2532.803% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -2089.832% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 14.419% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1601.259% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -8183.861% |
| Exelixis, Inc. | 678.44 Million USD | 78.542% |
| Better Therapeutics, Inc. | 23.84 Million USD | -510.603% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 11.257% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 75.5% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1263.083% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -8866.406% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -273.982% |
| Gritstone bio, Inc. | 125.91 Million USD | -15.614% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -891.96% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -2760.89% |
| Avid Bioservices, Inc. | 275.66 Million USD | 47.19% |
| Insmed Incorporated | 1.66 Billion USD | 91.239% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1792.118% |
| MediWound Ltd. | 27.18 Million USD | -435.477% |
| OmniAb, Inc. | 87.4 Million USD | -66.568% |
| Alector, Inc. | 487.66 Million USD | 70.148% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 63.917% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -690.122% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -279.381% |
| Zai Lab Limited | 240.17 Million USD | 39.386% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 76.894% |
| Aura Biosciences, Inc. | 29.22 Million USD | -398.101% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -53.118% |
| Immunic, Inc. | 25.36 Million USD | -473.873% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -110.266% |
| Veracyte, Inc. | 93.71 Million USD | -55.337% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -5463.553% |
| FibroGen, Inc. | 585.72 Million USD | 75.145% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -737.485% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -22191.433% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -2474.15% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.099% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1675.799% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -73.264% |
| TG Therapeutics, Inc. | 169.08 Million USD | 13.901% |
| Galecto, Inc. | 5.89 Million USD | -2369.132% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1657.364% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 94.44% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -405.1% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1053.474% |
| XBiotech Inc. | 8.39 Million USD | -1633.714% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -891.96% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -173.75% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 59.907% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -441.512% |
| Theravance Biopharma, Inc. | 169 Million USD | 13.86% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 88.024% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 70.909% |
| Vaxxinity, Inc. | 30.94 Million USD | -370.463% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 85.03% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -2313.819% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 80.465% |
| NexImmune, Inc. | 5.08 Million USD | -2763.363% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -39098.264% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -4634.543% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 97.952% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -2724.586% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1852.932% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -453.662% |
| Ainos, Inc. | 7.39 Million USD | -1868.834% |
| Pluri Inc. | 34.11 Million USD | -326.771% |
| Prothena Corporation plc | 135.01 Million USD | -7.823% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 40.116% |
| Celularity Inc. | 102.92 Million USD | -41.437% |
| Rallybio Corporation | 9.43 Million USD | -1442.815% |
| Cue Biopharma, Inc. | 24.44 Million USD | -495.541% |
| MeiraGTx Holdings plc | 319.99 Million USD | 54.505% |
| Omeros Corporation | 403.25 Million USD | 63.899% |
| Humacyte, Inc. | 114.67 Million USD | -26.948% |
| Immunocore Holdings plc | 228.15 Million USD | 36.193% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2886.256% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -89.705% |
| Blueprint Medicines Corporation | 918.64 Million USD | 84.153% |
| CalciMedica, Inc. | 4.02 Million USD | -3514.201% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -734.174% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 5.555% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -69.64% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 47.594% |
| Pulmatrix, Inc. | 15.96 Million USD | -811.984% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -822.97% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -491.644% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 41.956% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -186.654% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 87.975% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -358.044% |
| Nutriband Inc. | 1.07 Million USD | -13393.135% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -1269.134% |
| Vor Biopharma Inc. | 59.1 Million USD | -146.312% |
| Roivant Sciences Ltd. | 773.95 Million USD | 81.19% |
| Evogene Ltd. | 17.99 Million USD | -709.227% |
| ProKidney Corp. | 29.21 Million USD | -398.289% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -102.253% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -20550.143% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 92.293% |
| CorMedix Inc. | 11.91 Million USD | -1121.562% |
| BioLineRx Ltd. | 50.7 Million USD | -187.129% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 2.595% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -64.607% |
| Atai Life Sciences N.V. | 49.16 Million USD | -196.123% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -367.317% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -710.489% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -16.804% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -2474.814% |
| MediciNova, Inc. | 3.89 Million USD | -3640.923% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -696.433% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9577.97% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4035.935% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 63.354% |
| Biomea Fusion, Inc. | 30.69 Million USD | -374.356% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 94.651% |
| Mereo BioPharma Group plc | 15.96 Million USD | -812.041% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -366.588% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -148.074% |
| Absci Corporation | 58.3 Million USD | -149.691% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -664.28% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -354.058% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -97.29% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -66.409% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -331.093% |
| Allakos Inc. | 74.79 Million USD | -94.644% |
| Imunon, Inc. | 8.53 Million USD | -1606.597% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -546.993% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -26.799% |
| BioAtla, Inc. | 48.98 Million USD | -197.187% |
| NLS Pharmaceutics AG | 10.68 Million USD | -1263.083% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -5138.575% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -11.467% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -924.129% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -332.437% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -111.725% |
| aTyr Pharma, Inc. | 31.59 Million USD | -360.74% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -135.479% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -223.763% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -200.773% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -4972.474% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1684.502% |
| Akari Therapeutics, Plc | 4.58 Million USD | -3075.829% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -720.949% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 91.174% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -35942.861% |
| UroGen Pharma Ltd. | 243.52 Million USD | 40.219% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 54.66% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -5171.662% |
| Orgenesis Inc. | 35.53 Million USD | -309.681% |
| Entera Bio Ltd. | 1.37 Million USD | -10456.925% |
| GH Research PLC | 6.7 Million USD | -2072.512% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -2040.882% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -673.292% |
| Xencor, Inc. | 283.55 Million USD | 48.66% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -4775.949% |
| Replimune Group, Inc. | 113.21 Million USD | -28.588% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -3774.771% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -40.616% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -35942.861% |
| Portage Biotech Inc. | 4.45 Million USD | -3171.461% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -9577.97% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -531.584% |
| OncoCyte Corporation | 49.29 Million USD | -195.306% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -3419.141% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -18154.912% |
| Purple Biotech Ltd. | 10 Million USD | -1355.072% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -2416.073% |
| scPharmaceuticals Inc. | 57.26 Million USD | -154.239% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1075.168% |
| HilleVax, Inc. | 78.9 Million USD | -84.491% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -2782.772% |
| Tharimmune, Inc. | 1.81 Million USD | -7920.733% |
| Genprex, Inc. | 3.25 Million USD | -4373.592% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -436.819% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -2680.367% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -70569.903% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -40502.653% |
| OKYO Pharma Limited | 7.42 Million USD | -1861.771% |
| Savara Inc. | 37.19 Million USD | -291.428% |
| Curis, Inc. | 57.61 Million USD | -152.69% |
| Daré Bioscience, Inc. | 26.32 Million USD | -452.908% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -271.38% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -9981.717% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -599.265% |
| BeiGene, Ltd. | 2.23 Billion USD | 93.483% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -583.802% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 44.519% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -584.309% |
| Erasca, Inc. | 78.61 Million USD | -85.19% |
| bluebird bio, Inc. | 424.62 Million USD | 65.716% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22117.406% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 92.298% |
| DBV Technologies S.A. | 42.8 Million USD | -240.14% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -22117.406% |
| Moderna, Inc. | 4.57 Billion USD | 96.816% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1981.201% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -8691.063% |
| Molecular Templates, Inc. | 31.17 Million USD | -367.037% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -752.841% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 75.246% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -16.927% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -430.597% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -299.331% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -161.67% |
| MacroGenics, Inc. | 154.2 Million USD | 5.594% |
| RenovoRx, Inc. | 4.46 Million USD | -3159.74% |
| Adicet Bio, Inc. | 37.12 Million USD | -292.188% |
| Prime Medicine, Inc. | 60.78 Million USD | -139.52% |
| Aditxt, Inc. | 28.53 Million USD | -410.242% |
| Adagene Inc. | 45.16 Million USD | -222.298% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80464.026% |
| Quantum-Si incorporated | 26.63 Million USD | -446.656% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 79.13% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -4684.978% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -26.634% |
| SciSparc Ltd. | 1.59 Million USD | -9027.273% |
| Vericel Corporation | 127.7 Million USD | -13.997% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2516.043% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -70.552% |
| Generation Bio Co. | 171.63 Million USD | 15.178% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1160.433% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -248.019% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 42.39% |
| Invivyd, Inc. | 51.71 Million USD | -181.515% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -58.279% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -2137.884% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -92.831% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -14158.57% |
| 2seventy bio, Inc. | 310.12 Million USD | 53.058% |
| ADMA Biologics, Inc. | 193.97 Million USD | 24.949% |
| Clene Inc. | 38.95 Million USD | -273.752% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -302.902% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 43.349% |
| GeoVax Labs, Inc. | 3.51 Million USD | -4035.935% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 23.485% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1095.271% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 26.594% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1093.788% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -202.592% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -175.506% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 60.639% |
| Evaxion Biotech A/S | 17.61 Million USD | -726.338% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 9.538% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 4.965% |
| Trevena, Inc. | 48.26 Million USD | -201.645% |
| Surrozen, Inc. | 8.14 Million USD | -1687.354% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -574.138% |
| Cingulate Inc. | 10.36 Million USD | -1305.095% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -5193.818% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -290.379% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -3959.088% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1007.072% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 54.105% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -485.859% |
| Clearmind Medicine Inc. | 3.61 Million USD | -3932.678% |
| Kronos Bio, Inc. | 54.2 Million USD | -168.593% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -209.462% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -539.638% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -625.325% |
| Statera Biopharma, Inc. | 22.67 Million USD | -541.988% |
| ImmunityBio, Inc. | 1.09 Billion USD | 86.649% |
| Korro Bio, Inc. | 51.75 Million USD | -181.303% |
| Kineta, Inc. | 7.22 Million USD | -1915.785% |
| BioVie Inc. | 9.7 Million USD | -1400.495% |
| Codexis, Inc. | 49.94 Million USD | -191.475% |
| Celularity Inc. | 102.92 Million USD | -41.437% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -51.257% |
| Celcuity Inc. | 51.45 Million USD | -182.954% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -42073.387% |
| Cibus, Inc. | 206.11 Million USD | 29.37% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -242.743% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -452.717% |
| IN8bio, Inc. | 8.77 Million USD | -1559.599% |
| Kodiak Sciences Inc. | 213.59 Million USD | 31.842% |
| Annexon, Inc. | 47.11 Million USD | -208.969% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -62.585% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -51.06% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -963.482% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 94.408% |
| Eyenovia, Inc. | 19.78 Million USD | -635.986% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 17.791% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1795.326% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -504.091% |
| Arcellx, Inc. | 339.75 Million USD | 57.151% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1123.567% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 40.71% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -1422.326% |
| Moolec Science SA | 13.94 Million USD | -943.932% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -237.366% |
| Geron Corporation | 146.12 Million USD | 0.374% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -188.095% |
| Royalty Pharma plc | 6.29 Billion USD | 97.688% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -266.0% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -49348.72% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -5817.208% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 23.037% |
| Humacyte, Inc. | 114.67 Million USD | -26.948% |
| Structure Therapeutics Inc. | 29.05 Million USD | -401.119% |
| 89bio, Inc. | 59.96 Million USD | -142.783% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -450.127% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -12072.241% |
| Genelux Corporation | 8.42 Million USD | -1628.979% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -2023.396% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -6.794% |
| Notable Labs, Ltd. | 4.42 Million USD | -3188.457% |
| Liquidia Corporation | 73.13 Million USD | -99.048% |
| Mustang Bio, Inc. | 17.61 Million USD | -726.267% |
| Immunovant, Inc. | 48.95 Million USD | -197.375% |
| Quantum-Si incorporated | 26.63 Million USD | -446.656% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -279.282% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -4591.589% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -97.1% |
| Acasti Pharma Inc. | 11.55 Million USD | -1159.669% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -543.939% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -5255.344% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -294.772% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -10582.089% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -2288.123% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -486.189% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -527.933% |
| PepGen Inc. | 34.63 Million USD | -320.375% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1098.781% |
| United Therapeutics Corporation | 1.18 Billion USD | 87.686% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1984.479% |
| Solid Biosciences Inc. | 38.45 Million USD | -278.543% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1601.259% |
| Immuneering Corporation | 12 Million USD | -1112.323% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -46284.034% |
| Silo Pharma, Inc. | 1.56 Million USD | -9176.925% |
| Belite Bio, Inc | 4.21 Million USD | -3357.136% |
| XOMA Corporation | 145.58 Million USD | 0.0% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -5895.881% |
| Bionomics Limited | 10.15 Million USD | -1333.054% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -577.4% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -535.36% |
| uniQure N.V. | 624.01 Million USD | 76.671% |
| Cassava Sciences, Inc. | 14.19 Million USD | -925.572% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -80464.026% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 14.457% |
| Forte Biosciences, Inc. | 3.66 Million USD | -3871.086% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -55767.037% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -2057.7% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1795.326% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -737.485% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -1277.555% |
| Altimmune, Inc. | 16.54 Million USD | -780.116% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 76.432% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -535.36% |
| Compugen Ltd. | 55.77 Million USD | -161.013% |
| Peak Bio, Inc. | 20.75 Million USD | -601.477% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -31.791% |
| Benitec Biopharma Inc. | 4.96 Million USD | -2833.898% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 7.769% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -93.657% |
| Zura Bio Limited | 21.29 Million USD | -583.731% |
| PolyPid Ltd. | 17.46 Million USD | -733.41% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -29.521% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -93.657% |
| Instil Bio, Inc. | 99.8 Million USD | -45.87% |
| argenx SE | 444.95 Million USD | 67.282% |
| Immunome, Inc. | 28.65 Million USD | -407.991% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1646.192% |
| Verona Pharma plc | 58.84 Million USD | -147.413% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -905.873% |
| Shattuck Labs, Inc. | 14.85 Million USD | -879.743% |
| CervoMed Inc. | 2.59 Million USD | -5508.405% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2886.869% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1043.059% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -1281.87% |
| Moolec Science SA | 13.94 Million USD | -943.932% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -6112.065% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -161.857% |
| AnaptysBio, Inc. | 364.28 Million USD | 60.037% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1117.631% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1047.745% |
| NeurAxis, Inc. | 1.91 Million USD | -7511.075% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -273.972% |
| Lumos Pharma, Inc. | 13.33 Million USD | -991.877% |
| Achilles Therapeutics plc | 19.08 Million USD | -662.718% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -905.873% |
| 180 Life Sciences Corp. | 5.38 Million USD | -2602.327% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -517.178% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -539.638% |
| Nutriband Inc. | 1.07 Million USD | -13393.135% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -375.783% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -903.239% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 63.721% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -348.311% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1015.633% |
| Palisade Bio, Inc. | 2.73 Million USD | -5215.078% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -2671.369% |
| Beam Therapeutics Inc. | 478.38 Million USD | 69.568% |
| Neurogene Inc. | 36.54 Million USD | -298.315% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 63.418% |
| AEON Biopharma, Inc. | 159.88 Million USD | 8.949% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -205.519% |
| Sesen Bio, Inc. | 30.98 Million USD | -369.855% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -460.764% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1814.968% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 25.625% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 24.2% |
| Athira Pharma, Inc. | 30.05 Million USD | -384.346% |
| Vaccinex, Inc. | 5.94 Million USD | -2350.017% |
| HCW Biologics Inc. | 15.05 Million USD | -867.184% |
| XOMA Corporation | 145.58 Million USD | 0.0% |
| Nektar Therapeutics | 267.04 Million USD | 45.485% |
| Arvinas, Inc. | 644.6 Million USD | 77.415% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -720.949% |
| Merus N.V. | 102.15 Million USD | -42.515% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 0.526% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -53.049% |
| Rezolute, Inc. | 11.73 Million USD | -1140.668% |
| Clene Inc. | 38.95 Million USD | -273.752% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -5012.77% |
| BeyondSpring Inc. | 48.26 Million USD | -201.601% |
| Synlogic, Inc. | 32.89 Million USD | -342.56% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -896.236% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -8809.425% |
| Peak Bio, Inc. | 20.75 Million USD | -601.477% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -129.408% |
| Krystal Biotech, Inc. | 39.71 Million USD | -266.571% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 61.348% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -46.21% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -33542.536% |
| MannKind Corporation | 721.36 Million USD | 79.819% |
| Ikena Oncology, Inc. | 22.33 Million USD | -551.802% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -6878.907% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -41.905% |
| Gossamer Bio, Inc. | 249.14 Million USD | 41.569% |
| CohBar, Inc. | 1.03 Million USD | -13984.235% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -1261.961% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -664.28% |
| Legend Biotech Corporation | 589.93 Million USD | 75.323% |
| Mural Oncology plc | 37.92 Million USD | -283.833% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -9.759% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -6242.438% |
| Disc Medicine, Inc. | 22.87 Million USD | -536.415% |
| Champions Oncology, Inc. | 28.03 Million USD | -419.279% |
| REGENXBIO Inc. | 262.22 Million USD | 44.483% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -4233.574% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1061.481% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -983.86% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -586.536% |
| Vaxart, Inc. | 34.02 Million USD | -327.862% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -614.003% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -410.236% |
| Cellectis S.A. | 249.57 Million USD | 41.669% |
| Longeveron Inc. | 5.33 Million USD | -2627.75% |
| Repare Therapeutics Inc. | 41.81 Million USD | -248.119% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 93.947% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -141.154% |
| Revolution Medicines, Inc. | 262.39 Million USD | 44.519% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -6809.35% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1587.688% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1133.624% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -936.673% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -6668.015% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.173% |
| Denali Therapeutics Inc. | 122.96 Million USD | -18.393% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -2516.043% |
| Veru Inc. | 32.81 Million USD | -343.67% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -2019.377% |
| Cingulate Inc. | 10.36 Million USD | -1305.095% |
| Passage Bio, Inc. | 39.26 Million USD | -270.791% |
| Context Therapeutics Inc. | 4.19 Million USD | -3373.041% |
| Exicure, Inc. | 8.54 Million USD | -1602.889% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -393.358% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -1288.327% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -560.496% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 10.679% |
| Nuvalent, Inc. | 31.82 Million USD | -357.468% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -2188.408% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -130.999% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -708.778% |
| OmniAb, Inc. | 87.4 Million USD | -66.568% |
| Anew Medical, Inc. | 8.24 Million USD | -1666.362% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -280.213% |
| Lipocine Inc. | 2.63 Million USD | -5431.935% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -454.126% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -262.031% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -446.434% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -68.976% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -2595.427% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -75.934% |
| Ocugen, Inc. | 23.98 Million USD | -507.013% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -213.703% |
| Q32 Bio Inc. | 233.12 Million USD | 37.554% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1505.78% |
| Alumis Inc. Common Stock | 53.5 Million USD | -172.102% |
| Equillium, Inc. | 27.95 Million USD | -420.728% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 29.533% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -2487.323% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -2273.728% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 7.466% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -109.67% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -1359.566% |
| Dominari Holdings Inc. | 4.63 Million USD | -3040.885% |
| Edesa Biotech, Inc. | 1.84 Million USD | -7804.924% |
| vTv Therapeutics Inc. | 29.56 Million USD | -392.373% |
| Bio-Techne Corporation | 744.34 Million USD | 80.442% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -15.449% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 57.736% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -258.792% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -402.745% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -57.622% |
| Nkarta, Inc. | 105.6 Million USD | -37.86% |
| BioCardia, Inc. | 4.59 Million USD | -3071.678% |
| Iterum Therapeutics plc | 32.66 Million USD | -345.717% |